ASX:NEUPharmaceuticals
Neuren Pharmaceuticals (ASX:NEU) Shares Trade On Premium Despite Margin Compression
Neuren Pharmaceuticals went into this earnings print with a high growth label and a P/E of 131.5x, far above global pharma averages. Yet the stock closed at A$21.02 after a rough week that left it down about 9%. The headline from H1 2026 is not breakneck revenue acceleration; it is a compression story. Net profit margins on the trailing 12 months sit at 29.1% compared with 68.1% a year earlier, as earnings quality questions and heavy non cash items collide with a still premium valuation.
Love...